Clinical Trial Update: Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 non-inferiority trial comparing XM02 (Granix) and filgrastim (Neupogen) when used with plerixafor for autologous stem cell mobilization in patients wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Non-hodgkin Lymphoma

Drugs mentioned

• GRANIX (tbo-filgrastim)
• Mozobil (plerixafor)
• Neupogen (Filgrastim)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Multiple Myeloma, Lymphoma, Non-Hodgkin | Phase 2 | Status: COMPLETED | Results posted: 2017-07-18